Provided by Tiger Trade Technology Pte. Ltd.

Natera

212.12
-4.2400-1.96%
Post-market: 212.120.00000.00%18:41 EST
Volume:1.18M
Turnover:251.63M
Market Cap:29.34B
PE:-92.61
High:218.26
Open:216.36
Low:208.57
Close:216.36
52wk High:256.36
52wk Low:125.38
Shares:138.32M
Float Shares:135.00M
Volume Ratio:1.39
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2905
EPS(LYR):-1.5269
ROE:-29.02%
ROA:-12.89%
PB:23.43
PE(LYR):-138.93

Loading ...

Earning Preview: Natera this quarter’s revenue is expected to increase by 38.24%, and institutional views are broadly bullish

Earnings Agent
·
Feb 19

Press Release: Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

Dow Jones
·
Feb 17

Natera Inc. to Announce Fourth Quarter and Full Year Results

Reuters
·
Feb 17

Natera Launches EDEN Study to Assess Early Risk of Preeclampsia in Pregnancy

Reuters
·
Feb 06

Natera Inc. Chief Legal Officer Daniel Rabinowitz Reports Disposal of Common Shares

Reuters
·
Feb 05

Natera on Track for Longest Losing Streak Since September 2023 -- Data Talk

Dow Jones
·
Feb 04

Exploring US High Growth Tech Stocks This February 2026

Simply Wall St.
·
Feb 04

BRIEF-Natera Submits Signatera™ CDx PMA To FDA

Reuters
·
Feb 02

Natera Submits Signatera CDx Premarket Approval Application to FDA

Reuters
·
Feb 02

Natera Submits Signatera™ Cdx Pma to FDA

THOMSON REUTERS
·
Feb 02

Natera Inc - Submission Supported by Phase 3 Imvigor011 Trial Data

THOMSON REUTERS
·
Feb 02

The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh -- Barrons.com

Dow Jones
·
Feb 02

Natera Completes Enrollment in ACES-EMB Trial Evaluating Prospera Heart Test for Transplant Rejection Monitoring

Reuters
·
Jan 28

Natera Announces Completion of Enrollment in Randomized Aces-Emb Trial in Heart Transplantation

THOMSON REUTERS
·
Jan 28

Natera Inc. Co-Founder and Director Jonathan Sheena Reports Disposal of Common Shares

Reuters
·
Jan 28

Natera Study Shows Prospera Test Reduces Need for Routine Lung Transplant Biopsies

Reuters
·
Jan 26

Analysts’ Top Healthcare Picks: Natera (NTRA), Corcept Therapeutics (CORT)

TIPRANKS
·
Jan 22

Natera announces publication of validation study for Latitude tissue-free assay

TIPRANKS
·
Jan 21

Natera Launches Latitude Tissue-Free MRD Test With High Sensitivity in Colorectal Cancer Study

Reuters
·
Jan 21

Natera Showcases Fetal Focus Single Gene NIPT Clinical Trial Results at SMFM Meeting

Reuters
·
Jan 20